Host: The Japanese Society of Toxicology
Name : The 51st Annual Meeting of the Japanese Society of Toxicology
Date : July 03, 2024 - July 05, 2024
As the pharmaceutical industry faces high R&D costs and low productivity, there is a growing demand for the development and validation of physiological human cell models that can be implemented in the early stages of drug discovery phase. Therefore, to effectively and efficiently reproduce the human condition and ensure safety, there is a need for a paradigm shift from existing cell models that do not meet our research questions. There is also a need to properly qualify these Complex in vitro models（CIVMs） to make them suitable for various applications in advanced drug discovery and translational research. In addition, to utilize the output obtained from CIVMs in compound evaluation strategies, it is essential to use not only numerical data but also artificial intelligence and machine learning, and an interdisciplinary perspective is considered necessary.
This symposium is focused on the evaluation for preclinical safety in early phase of drug discovery from the hit/lead discovery stage to lead optimization. And then, I will overview the current status and issues of safety evaluation in early phase of drug discovery.
